Conjunctivitis in Tralokinumab-Treated Adult Patients with Moderate-To-Severe Atopic Dermatitis: Pooled Results from Five Clinical Trials

Main Article Content

Andreas Wollenberg
Lisa Beck
Marjolein de Bruin Weller
Rebecca Zachariae
Christina Olsen
Jacob Thyssen

Keywords

Atopic Dermatitis, Biologic, Tralokinumab, IL-13, Conjunctivitis

Abstract

Abstract not available.

References

1. Nutten S. Ann Nutr Metab 2015; 66 (Suppl 1): 8–16.

2. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

3. Eckert L et al. J Am Acad Dermatol 2017; 77: 274–279.e273.

4. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

5. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

6. Thyssen JP et al. J Am Acad Dermatol 2017; 77: 280–286.e281.

7. Akinlade B et al. Br J Dermatol 2019; 181: 459–473.

8. Faiz S. J Am Acad Dermatol 2019; 81: 142-151.

9. Bieber T. Allergy 2020; 75: 54–62.

10. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

11. Popovic B et al. J Mol Biol 2017; 429: 208–219.

Most read articles by the same author(s)